C-reactive protein: A new golden marker of cardiovascular risk;Proteína C reactiva: Um novo marcador «dourado» de risco cardiovascular

Revista Portuguesa de Cardiologia

Volumn 21, Issue 11, 2002, Pages 1329-1346

  Gomes, Mário Cerqueira ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular risk factors; Inflamation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SERUM AMYLOID A; STATIN; TUMOR NECROSIS FACTOR;

ARTERY GRAFT; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; INFLAMMATION; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; VEIN GRAFT;

ACUTE DISEASE; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HUMANS; INFLAMMATION MEDIATORS; RISK FACTORS; SYNDROME;

EID: 0036868833     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124 Suppl:S1-S9.
2. Ross R. Atherosclerosis - An inflammatory disease. New Engl J Med 1999;340;123-35.
3. Ross R. The pathogenesis of atherosclerosis. New Engl J Med 1976;295:369-77,420-25.
4. Farzaneh-Far AF, Rudd J, Weissberg PL. Myocardial ischemia: Inflammatory mechanisms. Brit Med Bull 2001;59: 55-68.
5. Patel BV, Robbins MA, Topol EJ. C-reactive protein: A "golden marker" for inflammation and coronary artery disease. Cleve Clin J Med 2001;68:521-34.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
7. Krishnaswamy G, Smith JK, Mukkamala R et al. Multifunctional cytokine expression by human coronary endothelium and glycocorticoids. Microvasc Res 1998;55:189-200.
8. Gonzalez-Amaro R, Diaz-Gonzalez F, Sánchez-Madrid F. Adhesion molecules in inflammatory diseases. Drugs 1998;56:977-88.
9. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ. Mechanisms in intimal monocytes-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation 1992;86:111-20-111-25.
10. Wang JM, Sica A, Peri G, et al. Expression of monocyte chemotactic protein-1 and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1166-74.
11. Blake JG, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;98:763-71.
12. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
13. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251:788-91.
14. Morrow DA, Ridker PM. Inflammation in cardiovascular disease. In: Topol EJ, (Editor) Textbook of Cardiovascular Medicine: Updates Vol. 2. Philadelphia: Lippincott 1999:1-12.
15. Betscholz C, Raines EW. Platelet-derived growth factor: A key regulator of connective tissue cells in embryogenesis and pathogenesis. Kidney Int 1997;51:1361-69.
16. Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors: Implications for the pathogenesis of atherosclerosis. Arteriosclerosis 1989;9:269-78.
17. Warner SJ, Libby P. Human vascular smooth muscle cells: Target for and source of tumor necrosis factor. J Immunol. 1989;142:100-9.
18. Barath P, Fishbein MC, Cao J, et al. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65;297-302.
19. Ng SB, Tan YH, Guy GR. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 1994;269:19021-27.
20. Saunceau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1 NF B, and Sp1 transcription factors. J Biol Chem 1995;270:27920-31.
21. Loppnow H, Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 1989;122:493-503.
22. Seino Y, Ikeda U, Ikeda M, et al. Interleukin-6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994;6:87-91.
23. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996;127:263-71.
24. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
25. Pepys MB. The acute phase response and C-reactive protein. In: Weartherall DJ, Ledingham JGG, Warrel DA, (eds.). Oxford Textbook of Medicine. 3rd Ed. Oxford: Oxford Univ Pr: 1996:1527-33.
26. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. Circulation 1996;4:2013-20.
27. van der Wall AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
28. Tenaglia AN, Buda AJ, Wilkins RG, et al. Levels of expression of P-selectin, E-selectin and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 1997;79:742-47.
29. Rifai N, Joubran R, Yu K, et al. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999;45:1967-73.
30. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-IRa and IL-6 during the first 2 days of hospitalisation in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079-84.
31. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-54.
32. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
33. Morrow DA, Rifai N, Antman L. Serum amyloid-A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy JACC 2000;35:358-63.
34. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina New Engl J Med 1994;331:417-24.
35. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. Comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285;2481-85.
36. Ristisch K. The race to develop tools to pinpoint arterial inflammation. Heartwire 2002; June 19.
37. Stefanadis C, Diamantopoulos L, Vachopoulos et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: A novel method of detection by application of a special thermography catheter. Circulation 1999;99;1965-71.
38. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-43.
39. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological application. Clin Chem 1997;43:52-8.
40. Ladue TB, Weiner DL, Sipe J, et al. Analytical evaluation of particle-enhanced immunonephelometric assay for C-reactive protein, serum amyloid A, and mannose-binding protein in human serum (abs). Clin Chem 1997;43:S240.
41. Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 1999; 130:933-9.
42. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
43. Lagrand WK, Visser AC, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999;100:96-102.
44. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
45. Lagrand WK, Niessen JWM, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
46. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.
47. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int 1995;45:635-41.
48. Zwaka TP, Hombach V, Torzewski J. C-protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001;103:1194-7.
49. Yasojima K, Schwab C, McGreer FG. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-51.
50. Pasceri V, Willerson JT, Yeh ET. Direct pro-inflammatory effect of C-reactive protein on human endothelial cells. Circulation 2001;103:1194-7.
51. Pasceri V, Yeh ET. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-6.
52. Tamai F, Crea F, Gaspardone A, et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 2001;101:1471-6.
53. Biasucci JM, de Maat MPM, Mee A, van der Greef, Summaria I, Maseri A. Analysis of activation markers of coagulation, fibrinolysis and inflammation in unstable angina by probit transformation. Fribrinolysis 1996;(suppl 2):145-47.
54. Pietilla KO, Harmoinen AP, Jokiniitty J, Pastemack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996;17:1345-49.
55. Anzai T, Yoshikava T, Shiraki H et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997; 96:778-84.
56. Tommasi S, Carluccio E, Bentivoglio M, et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 1999;83:1595-99.
57. Heeschen C, Hamn CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. (CAPTURE Investigators). JACC 2000;35:1535-42.
58. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. JACC 1998;31:1460-5.
59. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease (FRISC Study Group). New Engl J Med 2000;343:1139-47.
60. Ridker PM, Rifai N, Pfeffer, Sacks FM, Moye LA, Goldman, Flaker GC, Braunwald E (for the Cholesterol and Recurrent Events (CARE) Investigators). Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-84.
61. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-72.
62. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349; 462-6.
63. Biasucci LM, Liuzzo G, Grillo KL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99: 855-60.
64. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein and B-type natriuretic peptide. Circulation 2002;105:1760-3.
65. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-8.
66. Ikonomidis I, Andreotti F, Economou E, et al. Increased pro-inflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
67. Katritsis D, Korovesis S, Giazitzoglou E. C-reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem 2001;47:882-6.
68. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL (for the Intermountain Heart Collaboration Study Group). C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina. JACC 2002;39:632-7.
69. Buffon A, Liuzzo G, Biascucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. JACC 1999;34:1512-21.
70. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary interventions. Circulation 2001;104:992-7.
71. Bazzino O, Ferreiros ER, Pizarro R, et al. C-reactive protein and the stress test for risk stratification of patients recovering from unstable angina pectoris. Am J Cardiol 2001;87:1235-39.
72. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000;85:92-5.
73. Walter DH, Fichtscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. JACC 2001;37:839-46.
74. Milazzo D, Biassucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-61.
75. Chew DP, Bhatt DI, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-4.
76. Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pre-treatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-6.
77. Mehta SR, Yusuf S, Peter RI, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-33.
78. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after balloon angioplasty: Final results of the fluvastatin angioplastic restenosis (FLAKE) trial. Eur Heart J 1999; 20:58-69.
79. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at time of percutaneous coronary intervention. Circulation 2002;105: 691-6.
80. Eisenberg MS, Chen HJJ, Warshofski MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000;102:2100-4.
81. Gussekloo J, Schaap MCL, Frolich MB, et al. C-reactive protein is a strong but non-specific risk factor of fatal stroke in elderly. Arterioscler Thromb Vasc Biol 2000;20:1047-51.
82. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study. Stroke 2001; 32:2575-9.
83. van Excel, Gussekloo J, de Craen AJ, et al. Inflammation and stroke: The Leiden 85-Plus Study. Stroke 2002;33:1135-8.
84. Ridker PM, Cushman M, Stampfer J, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
85. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study (Multiple risk factor intervention trial). Am J Epidemiol 1996;144:537-47.
86. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997;336:973-9.
87. Koenig W, Sund M, Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
88. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-3.
89. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002;287:356-9.
90. Isomaa B, Almgren P, Toumi T, et al. Cardiovascular mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
91. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000;23:1835-9.
92. Yudkin JS, Stehouwer CDA, Emeis A. et al. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-78.
93. Hak AE, Stehouwer CDA, Bots ML, et al. Association of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-91.
94. Barinas-Michell E, Cushman M, Meilahn EN, et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001;153:1094-101.
95. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
96. Pannacciulli N, Cantatore FP, Minenna A, et al. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes 2001;25:1416-20.
97. Festa A, D'Agostino Jr R, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes 2001;25:1407-15.
98. Festa A, D'Agostino R Jr., Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;02:2-7.
99. Lemieux I, Pascot A, Prud'Homme D, et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
100. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 148;2:209-14.
101. Papanicolaou DA, Vgontzas AN. Interleukin-6: The endocrine cytokine. J Clin Endocrinol Metab 2000;5:331-2.
102. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-9.
103. Bastard JF, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85;3338-42.
104. Mohamed-Ali V, Goodrick S, Raweesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 82: 4196-200.
105. Vgontzas AN, Bixler EO, Papanicolaou DA, et al. Chronic systemic inflammation in overweight and obese adults (Letter). JAMA 2000;283:2285.
106. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 1999;52:465-77.
107. Libby P, Ridker PM, Maseri A. Inflammation and atheroselerosis. Circulation 2002;105:1135-43.
108. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: A population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
109. Sergi M, Rizzi M, Comi AL, et al. Sleep apnea in moderate-severe obese patients. Sleep Breath 1999;3:47-52.
110. Laaban JP, Cassuto D, Orvoen-Friza E, et al. Cardiorespiratory consequences of sleep apnoea syndrome in patients with massive obesity. Eur Respir J 1998;11:20-7.
111. Sanz CZ, Gonzalez BJ, Salgueiro RM, Rodriguez S Jr. Sleep apnea syndrome and cardiovascular diseases. Ann Med Int 2001;18:274-9.
112. Duchna HW, Guilleminault C, Stoohs RA, et al. Obstructive sleep apnea syndrome: A cardiovascular risk factor. Z Kardiol 2001;90:568-75.
113. Ip MSM, Lam KS, Chung-man H, et al. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000;118:580-6.
114. Vgontzas AN, Dimitris A, Papanicolaou DA, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6.
115. Vgontzas A, Dimitris A, Papanicolaou DA, et al. Sleep apnea and daytime sleepiness and fatigue: Relation with visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.
116. Shamsuzzaman ASM, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462-4.
117. Kilpatrick ES, Keevil BG, Jagger C, et al. Determinants of raised C-reactive protein concentration in type 1 diabetes. Quart J Med 2000;93:231-6.
118. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoom study. Arterioscler Thromb Vasc Biol 1999;19:3071-8.
119. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland coronary prevention study. Diabetes 2002;51:1596-600.
120. Festa A, D'Agostino R Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activation inhibitor-1 predict the development of type-2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002; 51:1131-37.
121. Jeffrey S. Type 2 diabetes may have inflammation component. Heartwire 2002;27 June 2002.
122. Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 1999;130:933-7.
123. Koenig W, Pepys M. C-reactive protein risk prediction: Low specificity, high sensitivity. Ann Intern Med 2002;136: 550-2.
124. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
125. Aizawa Y, Kawabe J, Hasebe N, et al. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001;104:455-60.
126. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-38.
127. Haffner SM, Grennberg A, Weston W, et al. Effects of rosiglitazone treatment on levels of C-reactive protein and MMP9 in patients with type 2 diabetes. Circulation 2001;104:11-117.
128. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.
129. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-70.
130. LaMonte MJ, Durstine JL, Yanowitz FG, et al. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation 2002;105;403-6.
131. Vorchheimer DA, Fuster V. Inflammation markers in coronary artery disease: Let prevention douse the flames. JAMA 2001;286:2154-6.